Employees: 174
Size Rigel Pharmaceuticals (RIGL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $801M, the 2367th largest of 3,085 United States companies the cockpit tracks. Shares closed at $42.53 on 18 Nov 2026.
Performance Over six months the shares gained 47.6%, against -8.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue grew 2.2% over the last twelve months (peer median +2.7%); the operating margin is 26.3% (peer median 5.0%).
Valuation It trades at 10.8× forward earnings against a peer median of 19.6× (4th cheapest of 8).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -21 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.5 points above its cost of capital (11.4% WACC).
Short interest Short interest is 13.5% of the free float (30 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $288M | $294M | $179M | $117M | $120M |
| Revenue growth | — | +64% | +53% | -3% | — |
| Gross profit | $258M | $275M | $161M | $110M | $118M |
| EBITDA | $79.6M | $128M | $26.4M | -$19.3M | -$53.2M |
| Net income | $307M | $367M | $17.5M | -$25.1M | -$58.6M |
| Free cash flow | $89.9M | $75.7M | $31.4M | -$5.74M | -$74.2M |
| Capital expenditure | $70.6M | $0 | $396,000 | $15.0M | $450,000 |
| Total debt | $7.79M | $53.3M | $60.0M | $60.6M | $41.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RIGL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.6% | -2.9% | 6th lowest of 19 |
| 6-month return | +47.6% | -8.3% | 2nd highest of 19 |
| Distance from 52-week high | -19.1% | -34.8% | 4th highest of 19 |
| Revenue growth (TTM) | +2.2% | +2.7% | 10th highest of 19 |
| Operating margin | 26.3% | 5.0% | 3rd highest of 19 |
| Forward P/E | 10.8× | 19.6× | 4th cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | 1.5% | 6.6% | 4th least demanding of 10 |
| Growth delivered (Del g) | +22.1% | +10.1% | 3rd highest of 10 |
| Hurdle (Req g minus delivered) | -20.6 pp | -5.1 pp | 2nd least demanding of 10 |
| ROIC minus cost of capital | +5.5 pp | -2.3 pp | 4th highest of 18 |
| EV / EBITDA | 8.9× | 9.7× | 4th cheapest of 7 |
| Net debt / EBITDA | -1.1× | 0.3× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 10.8× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 24.3× | 13.9% | +27.7% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 19.6× | 16.3% | -8.7% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 3.7× | -2.6% | +20.3% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 42.2× | 6.6% | +17.7% |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 3.5× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 10.4× | 4.6% | +22.5% |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | n/a | -2.5% | +2.6% |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 252.9× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | n/a | 33.9% | +10.1% |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | n/a | -3.8% | -0.8% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | n/a | n/a | n/a |